Compare DexCom, Inc. (DXCM) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares MBS ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while iShares MBS ETF trades at $89.79 (market cap $35.41B). The key difference: DexCom, Inc. and iShares MBS ETF are close in size by market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares MBS ETF for 96 Days on average.
| DXCM | MBB | |
|---|---|---|
Market Cap | $31.86B | $35.41B |
Volume | 3,607,070 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $96.91 |
52-Week Low | $54.84 | $89.09 |
Typical Hold Time | 62 Days | 96 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
MBB (iShares MBS ETF) trades at $89.73 with a slight 0.57% daily gain, though technical indicators signal bearish momentum with moving averages and ADX both in sell territory. The ETF recently hit a 52-week low of $91.02 in September 2026, reflecting pressure from rising intermediate-term rates and inflation concerns. Recent institutional activity shows mixed sentiment, with Corient Private Wealth increasing its position by 28.3% while short interest surged 98.3% to 6.57 million shares as of September 15, 2026.
The outlook remains cautious due to interest rate sensitivity and convexity risk in mortgage-backed securities. While Norway's $2.3 trillion sovereign wealth fund rotation into MBS provides institutional support, the intermediate duration of 5.68 years exposes MBB to Fed policy uncertainty. Key risks include persistent inflation and borrower prepayment behavior limiting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
